Phase
Condition
Congenital Adrenal Hyperplasia
Male Hormonal Deficiencies/abnormalities
Treatment
AAV BBP-631
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria
Adult male and non-pregnant females with classic CAH (simple virilizing or salt-wasting) due to 21-OHD
Screening/baseline 17-OHP levels > 5-10 × ULN and < 40 × ULN (upper limit of normal)
Stable oral hydrocortisone (HC) regimen as the only glucocorticoid (GC) maintenance therapy
Naïve to prior gene therapy or AAV-mediated therapy
Key Exclusion Criteria
Positive for anti-AAV5 (Adeno-Associated Virus Type 5) antibodies
History of adrenalectomy and/or significant liver disease
Study Design
Study Description
Connect with a study center
PARC Clinical Research, CALHN Royal Adelaide Hospital
Adelaide, South Australia 5000
AustraliaSite Not Available
Children's Hospital Los Angeles
Los Angeles, California 90027
United StatesSite Not Available
UCSF Benioff Children's Hospital, Oakland
Oakland, California 94609
United StatesSite Not Available
Rady Children's Hospital - San Diego
San Diego, California 92123
United StatesSite Not Available
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois 60611
United StatesSite Not Available
National Institutes of Health Clinical Center
Bethesda, Maryland 20892-1932
United StatesSite Not Available
University of Minnesota
Minneapolis, Minnesota 55455
United StatesSite Not Available
Lucas Research, Inc.
Morehead City, North Carolina 28557
United StatesSite Not Available
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania 19104
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.